XRCC6P5 and Huntington disease: While the use of Antisense Oligonucleotides (ASOs), RNA Interference, RNA Splicing Modification and DNA Repair Proteins (Wiggins and Feigin, 2021) hold some promise, clinical trials do not include premanifest HD patients or those with the early-onset juvenile HD (Wiggins and Feigin, 2021), further impeding the development of HD therapeutic strategies.